The long term objectives of this project are to understand the immunological and genetic basis for susceptibility to tuberculosis. As the effectiveness of cellular immunity to Mycobacterium tuberculosis determines whether infection evolves into clinical disease, a better understanding of the immune response and the genes that govern it will facilitate a more rational approach to development and use of vaccines, drugs, and biological therapy. An aerosol route of inoculation will be used to infect intact mice that are either inherently resistant or susceptible to tuberculosis. The local immune response in the lung will be compared to the systemic response in the spleen using a variety of techniques including the quantitation of T cell subsets, intracellular cytokines staining, and RNAse protection assays in order to define immunological parameters that indicate a protective immune response. Other investigations will ascertain which genetic loci are critical for disease resistance. With this insight, these techniques will be applied to interventional models to determine how different treatment strategies modify the immune response during primary infection (in the case of vaccines and biological treatments) or after subsequent rechallenge (in the case of chemotherapy). Finally, two different models that approximate the cell mediated defects observed in HIV/AIDS will be examined to determine how the immune response is altered to M. tuberculosis infection in the absence of CD4 plus T cells, and whether therapeutic interventions can beneficially augment the innate and adaptive immune responses under these conditions.
The specific aims are as follows:
Aim 1. Characterize the immunological differences between mouse strains that are either resistant or susceptible to infection with Mycobacterium tuberculosis after aerosol inoculation.
Aim 2. Determine the genetic derangements that correlate with susceptibility and resistance.
Aim 3. Identify how the immune response to tuberculosis changes as a consequence of therapeutic interventions in an animal model.
Aim 4. Characterize the immune response to tuberculosis in mouse models that simulate the abnormalities of cell mediated immunity typical of HIV/AIDS patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL064540-04
Application #
6527466
Study Section
Special Emphasis Panel (ZHL1-CSR-Q (S2))
Program Officer
Peavy, Hannah H
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
4
Fiscal Year
2002
Total Cost
$423,750
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Kamath, Arati B; Alt, Jennifer; Debbabi, Hajer et al. (2004) The major histocompatibility complex haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect Immun 72:6790-8
Chackerian, Alissa A; Alt, Jennifer M; Perera, Thushara V et al. (2002) Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70:4501-9
Chackerian, Alissa; Alt, Jen; Perera, Vaji et al. (2002) Activation of NKT cells protects mice from tuberculosis. Infect Immun 70:6302-9
Chackerian, A A; Perera, T V; Behar, S M (2001) Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 69:2666-74
Behar, S M; Cardell, S (2000) Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions. Semin Immunol 12:551-60